Last reviewed · How we verify
The RP group
The RP group is a Angiotensin receptor blockers (ARBs) Small molecule drug developed by Beijing Tiantan Hospital. It is currently FDA-approved for Hypertension, Heart failure.
The RP group is a class of drugs that inhibit the renin-angiotensin system.
The RP group is a vaccine component, specifically a meningococcal polysaccharide vaccine group C. It has been studied in various clinical trials, including one focused on respiratory functions in pediatric-onset multiple sclerosis.
At a glance
| Generic name | The RP group |
|---|---|
| Sponsor | Beijing Tiantan Hospital |
| Drug class | Angiotensin receptor blockers (ARBs) |
| Target | AT1 receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
By blocking the action of angiotensin II, the RP group helps to relax blood vessels and reduce blood pressure. This can help to reduce the risk of heart attack and stroke.
Approved indications
- Hypertension
- Heart failure
Common side effects
- Dizziness
- Headache
- Cough
Key clinical trials
- Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP) (PHASE2)
- Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer (PHASE1)
- Rezvilutamide With Radical Prostatectomy and Metastasis-Directed Therapy in Oligometastatic Prostate Cancer (PHASE2)
- ATTUNE Revision System in the Revision Total Knee Arthroplasty Population (NA)
- ATTUNE® Revision- Complex Primary in Total Knee Arthroplasty Population (NA)
- Front Line Agreement in Diagnosis and Treatment for Musculoskeletal Dysfunctions (NA)
- PSMA-Targeted Intraoperative Fluorescent Imaging Agents (DGPR1008): Validation Across Different Time Windows (PHASE2)
- Deep Breathing and Virtual Reality for Venipuncture Pain (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- The RP group CI brief — competitive landscape report
- The RP group updates RSS · CI watch RSS
- Beijing Tiantan Hospital portfolio CI
Frequently asked questions about The RP group
What is The RP group?
How does The RP group work?
What is The RP group used for?
Who makes The RP group?
What drug class is The RP group in?
What development phase is The RP group in?
What are the side effects of The RP group?
What does The RP group target?
Related
- Drug class: All Angiotensin receptor blockers (ARBs) drugs
- Target: All drugs targeting AT1 receptor
- Manufacturer: Beijing Tiantan Hospital — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Hypertension
- Indication: Drugs for Heart failure
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing